In the past week, CLYM stock has gone down by -9.23%, with a monthly decline of -36.23% and a quarterly plunge of -48.05%. The volatility ratio for the week is 11.52%, and the volatility levels for the last 30 days are 8.41% for Climb Bio Inc The simple moving average for the past 20 days is -20.70% for CLYM’s stock, with a -43.34% simple moving average for the past 200 days.
Is It Worth Investing in Climb Bio Inc (NASDAQ: CLYM) Right Now?
Additionally, the 36-month beta value for CLYM is -0.36. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CLYM is 51.90M and currently, short sellers hold a 9.59% ratio of that float. The average trading volume of CLYM on November 15, 2024 was 539.77K shares.
CLYM) stock’s latest price update
The stock price of Climb Bio Inc (NASDAQ: CLYM) has dropped by -9.49 compared to previous close of 3.53. Despite this, the company has seen a fall of -9.23% in its stock price over the last five trading days. globenewswire.com reported 2024-11-12 that Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of Gary Hao, Ph.D.
CLYM Trading at -41.00% from the 50-Day Moving Average
After a stumble in the market that brought CLYM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.34% of loss for the given period.
Volatility was left at 8.41%, however, over the last 30 days, the volatility rate increased by 11.52%, as shares sank -34.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -57.79% lower at present.
During the last 5 trading sessions, CLYM fell by -9.23%, which changed the moving average for the period of 200-days by +11.13% in comparison to the 20-day moving average, which settled at $4.03. In addition, Climb Bio Inc saw 18.33% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLYM starting from Pimblett Emily, who sale 1,191 shares at the price of $8.18 back on Sep 20 ’24. After this action, Pimblett Emily now owns 7,564 shares of Climb Bio Inc, valued at $9,741 using the latest closing price.
Morisset Valerie, the EVP, R&D AND CSO of Climb Bio Inc, sale 69,005 shares at $8.03 during a trade that took place back on Jul 22 ’24, which means that Morisset Valerie is holding 31,317 shares at $554,170 based on the most recent closing price.
Stock Fundamentals for CLYM
Equity return is now at value -42.08, with -41.27 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 57.73.
Conclusion
In conclusion, Climb Bio Inc (CLYM) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
